Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-383-5 | CAS number: 27277-00-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
Description of key information
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
Effect on neurotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on neurotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The test substance is a known emetic in humans (Bayliss, 1973) therefore tests in non-vomiting species are less relevant. These studies were all performed in rat and mice, which are non-vomiting species. It should be noted that the dosed test substance might be more available for absorption in non-vomiting species compared to vomiting species.
The test substance shows in experimental animals a variety of effects also shown at comparable doses by many of the drugs used in the treatment of mental disease. The profile of activities of the test substance is not, however, the same as any of the known clinically useful drugs. Some of these standard drugs, such as the benzdiazepines (e.g. chlordiazepoxide) and the barbiturates, protect mice from electroshock. The test substance does not, but it shares with these two types of drug the properties of decreasing both the motility of mice and the time that these animals balance on a stationary or rotating rod. This decrease of agility and motility is shown by such drugs as the phenothiazines (e.g. chlorpromazine) and the propiophenones (e.g. haloperidol). These two drugs decrease the temperature of mice which is a property shared by the test substance. Under the conditions chosen, these two types of drug decrease the amount of food eaten by starved mice; at relatively low doses the test substance has the same effect . The response of mice to intraperitoneal acetic acid (squirming movements) is decreased by the test substance which also increased the reaction time of the animals when placed on a hot plate. These effects could be due to an analgesic action. Like many drugs used as sedatives, the test substance increases the time required by mice to regain their righting reflexes after treatment with barbiturates. The tricyclic antidepressants (e.g. imipramine) antagonise the hypothermic action of reserpine on mice. They do not affect their temperature, agility, motility or food intake. The hypothermic action of reserpine on mice is antagonised by the test substance. This effect shown at relatively low doses is not due to inhibition of the enzyme monoamine oxidase. The antidepressant drugs of the imipramine type potentiate the action of adrenalin and other catecholamines on the nictitating membrane of the cat; the test substance does not. It is, therefore, unlikely that the increase of the temperature of reserpinised mice by the test substance is due to a potentiation of catecholamines as is thought to be the case with imipramine. In mice, the test substance slightly increases the toxicity of d-amphetamine.
Under the conditions chosen, the test substance alters the electrocorticogram of conscious rats in the same direction as d-amphetamine and in a different direction to imipramine. In contrast, the test substance has, in animals, many of the properties of the drugs which depress the central nervous system. These results also show that these actions are not identical in all respects with those of any of the major types of drug used in the treatment of mental disease.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.